The pharmaceutical industry trade and lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA) sued California state officials in federal court on December 8, 2017, over California’s new drug pricing law, which the group states is “unprecedented and unconstitutional.”
The pharmaceutical industry trade and lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA) sued California state officials in federal court on December 8, 2017, over California’s new drug pricing law, Senate Bill 17 (SB 17), which the group states is “unprecedented and unconstitutional.” PhRMA argues that the California law, set to take effect January 1, 2019, “intentionally exports California’s policy choices regarding prescription drug pricing on the entire nation.”
The law, which was signed by Democratic Governor Jerry Brown on October 9, 2017, requires drug makers to provide 60 days’ notice of price increases above 16% when combined with increases from the previous 2 years, and they must also justify those increases. In addition, insurers will have to provide information about how drug costs affect premiums.
The bill would also require the California Office of Statewide Health Planning and Development (OSHPD) to enforce the provisions requiring manufacturer reporting, and would subject a manufacturer to liability for a civil penalty if the information described above is not reported. Some of the pricing information will be available to the public on OSHPD’s website. “Californians have the right to know why their medication costs are out of control, especially when pharmaceutical profits are soaring,” Governor Brown said in a statement.
In its complaint, PhRMA argues that SB 17 “forces drug manufacturers to publicly convey and implicitly endorse the state’s position that the manufacturers are to blame for the allegedly inflated prices of prescription drugs.” Further, the group says the law incorrectly and unfairly singles out drug makers for public condemnation, and will cause market disruptions such as drug stockpiling and reduced competition. The group seeks a court declaration that the law violates the First Amendment, the Fourteenth Amendment, and the Commerce Clause.
The bill’s sponsor, State Senator Ed Hernandez, said he was confident the law would be upheld, and said the lawsuit was another example of pharma refusing to accept any responsibility for the skyrocketing costs of prescription drugs.
Analysts have noted that PhRMA is concerned that the California law has been signed because California is such a large state, and could potentially serve as a model for other states seeking to act on drug prices. Maryland and Nevada are also implementing their own drug pricing legislation. PhRMA spent nearly $17 million in the last several years to oppose SB 17 before it was signed into law.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.